scintillation proximity assay spa beads (Revvity)
Revvity is a verified supplier 
Revvity manufactures this product 
90
Structured Review
Revvity
scintillation proximity assay spa beads
Scintillation Proximity Assay Spa Beads, supplied by Revvity, used in various techniques. Bioz Stars score: 90/100, based on 16 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/scintillation+proximity+assay+spa+beads/WGA+PVT+500+MG+SPA+Beads/pm33939425-707-29-53
Average 90 stars, based on 16 article reviews
Scintillation Proximity Assay Spa Beads, supplied by Revvity, used in various techniques. Bioz Stars score: 90/100, based on 16 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/scintillation+proximity+assay+spa+beads/WGA+PVT+500+MG+SPA+Beads/pm33939425-707-29-53
Average 90 stars, based on 16 article reviews
scintillation proximity assay spa beads - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Serial Dilution:Article Title: Discovery of the S1P2 Antagonist GLPG2938 (1-[2-Ethoxy-6-(trifluoromethyl)-4-pyridyl]-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea), a Preclinical Candidate for the Treatment of Idiopathic Pulmonary Fibrosis. Article Snippet: Mounting evidence from the literature suggests that blocking S1P2 receptor (S1PR2) signaling could be effective for the treatment of idiopathic pulmonary fibrosis (IPF).. However, only a few antagonists have been so far disclosed.. A chemical enablement strategy led to the discovery of a pyridine series with good antagonist activity. Membrane:Article Title: Discovery of the S1P2 Antagonist GLPG2938 (1-[2-Ethoxy-6-(trifluoromethyl)-4-pyridyl]-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea), a Preclinical Candidate for the Treatment of Idiopathic Pulmonary Fibrosis. Article Snippet: Mounting evidence from the literature suggests that blocking S1P2 receptor (S1PR2) signaling could be effective for the treatment of idiopathic pulmonary fibrosis (IPF).. However, only a few antagonists have been so far disclosed.. A chemical enablement strategy led to the discovery of a pyridine series with good antagonist activity. Scintillation Proximity Assay:Article Title: Discovery of the S1P2 Antagonist GLPG2938 (1-[2-Ethoxy-6-(trifluoromethyl)-4-pyridyl]-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea), a Preclinical Candidate for the Treatment of Idiopathic Pulmonary Fibrosis. Article Snippet: Mounting evidence from the literature suggests that blocking S1P2 receptor (S1PR2) signaling could be effective for the treatment of idiopathic pulmonary fibrosis (IPF).. However, only a few antagonists have been so far disclosed.. A chemical enablement strategy led to the discovery of a pyridine series with good antagonist activity. Article Title: Discovery of 9-Cyclopropylethynyl-2-((S)-1-[1,4]dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one (GLPG1205), a Unique GPR84 Negative Allosteric Modulator Undergoing Evaluation in a Phase II Clinical Trial Article Snippet: .. First, 50 μL of hit compound from HTS was added into the assay plate, 747 followed by addition of 20 μL DIM at EC80 concentration (concentration which give 748 80% of the activity of GPR84) and were incubated with 30 μL of mixture consisting of 749 membranes derived from stable cell line overexpressing recombinant human 750 GPR84, [35S]GTPγS and Derivative Assay:Article Title: Discovery of the S1P2 Antagonist GLPG2938 (1-[2-Ethoxy-6-(trifluoromethyl)-4-pyridyl]-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea), a Preclinical Candidate for the Treatment of Idiopathic Pulmonary Fibrosis. Article Snippet: Mounting evidence from the literature suggests that blocking S1P2 receptor (S1PR2) signaling could be effective for the treatment of idiopathic pulmonary fibrosis (IPF).. However, only a few antagonists have been so far disclosed.. A chemical enablement strategy led to the discovery of a pyridine series with good antagonist activity. Article Title: Discovery of 9-Cyclopropylethynyl-2-((S)-1-[1,4]dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one (GLPG1205), a Unique GPR84 Negative Allosteric Modulator Undergoing Evaluation in a Phase II Clinical Trial Article Snippet: .. First, 50 μL of hit compound from HTS was added into the assay plate, 747 followed by addition of 20 μL DIM at EC80 concentration (concentration which give 748 80% of the activity of GPR84) and were incubated with 30 μL of mixture consisting of 749 membranes derived from stable cell line overexpressing recombinant human 750 GPR84, [35S]GTPγS and Stable Transfection:Article Title: Discovery of the S1P2 Antagonist GLPG2938 (1-[2-Ethoxy-6-(trifluoromethyl)-4-pyridyl]-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea), a Preclinical Candidate for the Treatment of Idiopathic Pulmonary Fibrosis. Article Snippet: Mounting evidence from the literature suggests that blocking S1P2 receptor (S1PR2) signaling could be effective for the treatment of idiopathic pulmonary fibrosis (IPF).. However, only a few antagonists have been so far disclosed.. A chemical enablement strategy led to the discovery of a pyridine series with good antagonist activity. Article Title: Discovery of 9-Cyclopropylethynyl-2-((S)-1-[1,4]dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one (GLPG1205), a Unique GPR84 Negative Allosteric Modulator Undergoing Evaluation in a Phase II Clinical Trial Article Snippet: .. First, 50 μL of hit compound from HTS was added into the assay plate, 747 followed by addition of 20 μL DIM at EC80 concentration (concentration which give 748 80% of the activity of GPR84) and were incubated with 30 μL of mixture consisting of 749 membranes derived from stable cell line overexpressing recombinant human 750 GPR84, [35S]GTPγS and Concentration Assay:Article Title: Discovery of 9-Cyclopropylethynyl-2-((S)-1-[1,4]dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one (GLPG1205), a Unique GPR84 Negative Allosteric Modulator Undergoing Evaluation in a Phase II Clinical Trial Article Snippet: .. First, 50 μL of hit compound from HTS was added into the assay plate, 747 followed by addition of 20 μL DIM at EC80 concentration (concentration which give 748 80% of the activity of GPR84) and were incubated with 30 μL of mixture consisting of 749 membranes derived from stable cell line overexpressing recombinant human 750 GPR84, [35S]GTPγS and Activity Assay:Article Title: Discovery of 9-Cyclopropylethynyl-2-((S)-1-[1,4]dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one (GLPG1205), a Unique GPR84 Negative Allosteric Modulator Undergoing Evaluation in a Phase II Clinical Trial Article Snippet: .. First, 50 μL of hit compound from HTS was added into the assay plate, 747 followed by addition of 20 μL DIM at EC80 concentration (concentration which give 748 80% of the activity of GPR84) and were incubated with 30 μL of mixture consisting of 749 membranes derived from stable cell line overexpressing recombinant human 750 GPR84, [35S]GTPγS and Incubation:Article Title: Discovery of 9-Cyclopropylethynyl-2-((S)-1-[1,4]dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one (GLPG1205), a Unique GPR84 Negative Allosteric Modulator Undergoing Evaluation in a Phase II Clinical Trial Article Snippet: .. First, 50 μL of hit compound from HTS was added into the assay plate, 747 followed by addition of 20 μL DIM at EC80 concentration (concentration which give 748 80% of the activity of GPR84) and were incubated with 30 μL of mixture consisting of 749 membranes derived from stable cell line overexpressing recombinant human 750 GPR84, [35S]GTPγS and Recombinant:Article Title: Discovery of 9-Cyclopropylethynyl-2-((S)-1-[1,4]dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one (GLPG1205), a Unique GPR84 Negative Allosteric Modulator Undergoing Evaluation in a Phase II Clinical Trial Article Snippet: .. First, 50 μL of hit compound from HTS was added into the assay plate, 747 followed by addition of 20 μL DIM at EC80 concentration (concentration which give 748 80% of the activity of GPR84) and were incubated with 30 μL of mixture consisting of 749 membranes derived from stable cell line overexpressing recombinant human 750 GPR84, [35S]GTPγS and |